Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care

• Published in: Drugs (New York, N.Y.) Vol. 81; no. 12; pp. 1373 - 1379
• Main Authors: Jacob, Stephan, Krentz, Andrew J., Deanfield, John, Rydén, Lars
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.08.2021; Springer Nature B.V
• Subjects: Agonists; Blood pressure; Cardiology; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - etiology; Cardiovascular Diseases - prevention & control; Clinical trials; Complications; Congestive heart failure; Diabetes; Diabetes Complications - etiology; Diabetes Complications - prevention & control; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Diabetic Nephropathies - etiology; Diabetic Nephropathies - prevention & control; Drug therapy; GLP-1 receptor agonists; Glucagon-Like Peptide-1 Receptor - agonists; Glucose; Glycated Hemoglobin A - metabolism; Glycemic Control; Heart failure; Humans; Hyperglycemia; Hypoglycemia; Inhibitors; Internal Medicine; Kidneys; Medicine; Medicine & Public Health; Metabolism; Morbidity; Mortality; Normalizing; Patient Care Planning; Pharmacology/Toxicology; Pharmacotherapy; Receptors; Renal failure; Renal Insufficiency, Chronic - etiology; Renal Insufficiency, Chronic - prevention & control; Risk management; Risk reduction; Risk Reduction Behavior; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Therapy in Practice; United Kingdom > UK

For many years, clinical studies could not show that lowering glucose in patients with type 2 diabetes leads to better macrovascular outcomes. In the past few years, new data have shown that treatment with two classes of dugs developed as “glucose-lowering agents,” SGLT2 inhibitors and GLP-1 recepto...